HOUSTON, TEXAS, Dec. 05, 2016 -- Quanex Building Products Corporation (NYSE:NX) (“Quanex” or the “Company”) today announced that its Board of Directors declared a quarterly cash dividend of $0.04 per share on the Company’s common stock, payable December 30, 2016, to shareholders of record on December 15, 2016.
About Quanex
Quanex Building Products Corporation is an industry-leading manufacturer of components sold to Original Equipment Manufacturers (OEMs) in the building products industry. Quanex designs and produces energy-efficient fenestration products in addition to kitchen and bath cabinet components.
Investor Contact: Scott Zuehlke, 713-877-5327, [email protected] Media Contact: Valerie Calvert, 713-877-5305, [email protected]


Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 



